LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

To date, almost 400 reports of acute pancreatitis have been received from people using GLP-1 drugs such as Mounjaro, Wegovy, ...

A Houston neurologist had his medical license suspended following his arrest on charges that accuse him of soliciting a minor ...

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs, market share of individual therapies, and current ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

In today’s world, losing weight isn’t just about fitting into your old jeans—it’s about reclaiming your energy, confidence, ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.